Families, clinicians, and scientists working to understand USP9X-related syndrome, and to fund the research that will change it.
Most doctors have never heard of USP9X. Most families learn the word from a genetic test result.
Source: Simons Searchlight USP9X gene guide (Jan 2025); Project-USP9X review of public sources. "Found" means we did not find one; that does not prove none exists. The 110 figure counts clinical identifications, not everyone with the condition.
{{ activeBody }}
One welcoming place for families, clinicians, and researchers.
Plain-language explainers and shared data, with honest labels on what is known.
Practical guides for care, school, benefits, respite, and daily life.
Funding and coordination for research that has not been done yet.
USP9X is a gene on the X chromosome. Its protein works like a quality-control worker inside cells, removing tiny tags from other proteins, and it is especially active in the developing brain. When one copy is lost or altered in a girl, the result can be USP9X-related syndrome (MRXS99F). Most often the change arises new in the child.
Research is at an early stage. We will always tell you what is known, what is not, and what is only an idea.
Mechanism to care, in five steps. The label under each step shows how well that step is supported by the research we could read.
A loss-of-function change in one USP9X copy. USP9X is extremely sensitive to losing a copy: ClinGen gives it the top haploinsufficiency score (3), and it ranks as one of the genes least tolerant of loss.
USP9X is reported to escape X-inactivation, so the second copy does not make up the gap. A girl has half the usual dose.
Brain-cell growth and migration are affected in mice and cells. TGF-β, mTORC1 and Wnt signaling are implicated.
Delay or intellectual disability is near-universal. Nothing found predicts how strongly it shows in one child.
No USP9X-specific treatment or interventional trial was found. Today's help is therapies, school supports, and checks of the body systems involved.
Pick a body area. Where two sources disagree, both are shown and never averaged: they come from different cohorts with different definitions.
Frequencies come from small cohorts (17 to 39 people) that lean toward recognizable or more severe cases. A feature missing in your child is common and expected. Many figures come from abstracts or an AI-compiled secondary report that has not been checked against the original papers, so please treat them as a first draft. Male evidence is left out except as background.
Two girls with similar genetic changes can look very different. Here is what the research has and has not explained.
A girl has two X chromosomes, each with a USP9X gene. In USP9X-related syndrome one copy is altered. Choose a kind of change to see how the cell would read that copy, three letters at a time.
Letters pair A with T and C with G. The dashed box marks one altered pair, drawn for illustration.
The letters are an illustration made up for this page. They are not the real USP9X sequence and not anyone's result. The short block labeled intron stands for the start of the next non-coding stretch.
{{ varHow }}
{{ varEffect }}
{{ varKnow }}
Not drawn here: a structural change such as an X inversion that interrupts the gene (a single low-confidence report). To learn how a result is described on a lab report, look for the cDNA (c.) and protein (p.) names and ask the lab or a genetic counselor to walk through them.
Most often it is new in the child, and nobody did anything to cause it. A few families show other patterns.
The typical pattern for girls: the change arose for the first time (de novo), and parental tests are negative.
Documented: one variant in the 2020 Jolly paper came from a mother who carried it in only some of her cells (mosaic). This is why parental testing can still matter.
Documented: a mother with scoliosis and partial hearing loss passed on her variant (Jolly 2020).
Documented: an unaffected mother (Jolly 2020), and two sisters with the same variant but different effects (Li 2022). Penetrance in girls is high, about 95%, but not complete.
No numeric recurrence risk was found for USP9X. A genetic counselor can estimate it from the family's actual variant and parental results.
USP9X removes small tags from other proteins and so protects them from being cleared away. Seven partner genes are mapped below: one (SMAD4) is rated low to moderate evidence and six are rated low, because most evidence comes from mice, cells and cancer studies and not from children. Select a gene to see the details.
USP9X does not change the DNA of these genes. It acts on their proteins, mostly by keeping them stable. Gene symbols for RAPTOR (RPTOR), beta-catenin (CTNNB1) and Mind bomb (MIB1) were mapped from protein names. Several sources were not read in full.
The female syndrome was first described in 2016. The largest pooled set is 35 girls and women with 16 males for comparison. The number beside each paper is how many females it describes; pooled papers re-count earlier cases, so the numbers are not added.
There is no USP9X-specific guideline, so teams build care from the features each child has. These are the main threads, with honest labels on the evidence.
No USP9X-specific treatment exists. Care is a team effort: physical, occupational, speech and behavioral therapy, school supports, and treatment of medical problems as they arise. Simons Searchlight advises starting as early as possible, ideally before school. No study has measured how girls with USP9X respond to any therapy.
Speech and language is the most affected area, so communication devices and picture systems (AAC) are worth asking about. A review of 28 studies in children with autism or intellectual disability found AAC improved both AAC use and speech production, though speech gains were modest. This is evidence from other conditions, not from USP9X.
Seizures affect a minority of girls: 12% in one dataset and 24% in another. A neurologist leads the plan, and an EEG is used if seizures are suspected. No USP9X-specific medicine data exist. A fly study found that blocking USP9X reduced seizures, but girls with this syndrome already have too little USP9X, so it is not a treatment lead.
ACMG's 2021 guideline strongly recommends exome or genome sequencing as a first or second test for children with developmental delay, intellectual disability or birth anomalies. One secondary source reports about half of USP9X cases in DECIPHER are copy-number changes, so deletion testing matters. If a result is called uncertain, ask the lab to re-review about yearly: studies show reanalysis adds from about 3% up to 10 to 20% or more to diagnoses. X-inactivation testing has not proved useful for USP9X.
No USP9X-specific schedule exists. Simons Searchlight lists features that may warrant follow-up but gives no intervals. A reasonable team checks hearing, eyes, spine, hips, heart, kidneys, thyroid and growth, teeth, and development and behavior. That list is our synthesis from how often features are reported, not a guideline.
Published girls and women range from 2 years 7 months to 23 years. Dashed bands are approximate planning windows from general guidance, and USP9X-specific timing is unknown.
Spine and hip checks: scoliosis is described as progressive in the founding paper, so a schedule through growth is worth asking about (our inference, not a USP9X guideline). Puberty prep: general guidance is to teach body safety and hygiene before changes begin.
Tap an item to mark it covered. Ticks live on this page only and are not saved.
These are questions, not instructions. Project-USP9X does not give medical advice, and every decision belongs with your child's clinicians.
We found no school or daily-life studies specific to USP9X. Everything below comes from research and law about intellectual disability and speech and language needs in general, so treat it as a starting point for talks with the school and your doctors.
An IEP is a written plan with measurable goals, a list of services and the strongest legal protections under IDEA. A 504 plan mainly removes barriers and usually is not enough for a child who needs specialized instruction. The likely school categories are Intellectual Disability, Speech or Language Impairment, and sometimes Multiple Disabilities, plus Hearing or Visual Impairment if those apply. The school's evaluation decides, not the diagnosis alone.
The IEP team must consider the child's communication needs and whether she needs assistive technology devices and services (34 CFR 300.324). A 2023 review of 17 mostly single-case studies found positive outcomes for students with significant intellectual disability and complex communication needs, though few studies tested use beyond the training setting.
The law requires teaching alongside children without disabilities as much as is appropriate, and allows removal only when regular classes with supports cannot meet the child's needs. Research mostly links inclusion to better later outcomes, but it cannot say what is best for any one child.
Guidance recommends preparing before periods start: body changes, hygiene and body safety. The 2016 AAP and NASPAG report discourages suppression before periods begin, and a 2025 hospital guideline notes hormonal options can interact with anti-seizure medicines. Children with intellectual disability face higher abuse risk, so advance body-safety teaching and supervision plans are advised. USP9X-specific puberty timing data: none found.
Sleep problems are common in people with intellectual disability. Melatonin evidence is thin: three small trials, 35 children in all, showed only a shorter time to fall asleep. WHO advises an average of at least 60 minutes a day of moderate to vigorous activity for children. Nutrition evidence could not be read.
Every US state has a Parent Training and Information Center that helps families of children from birth to age 26 understand their rights, prepare for IEP meetings and use mediation. It is free.
US details. Rules differ by state and this is not legal advice. Federal regulations are current to the pages read in October 2026.
No USP9X-specific foundation was found, so Project-USP9X is built to fill that gap. Until then these groups and programs can help. Check each one yourself before sharing health details.
Fill the gaps while the USP9X community is small.
Ask early, because waiting lists can be long.
Caring for the whole family.
Benefit figures are US examples from 2026 agency pages. Eligibility depends on your state and household, and a social worker is the best guide.
Everything for USP9X is early. This shows how far each idea has travelled, and what you can join today.
Observational research only. Neither is a treatment trial.
A USP9X Facebook group is linked from Simons Searchlight, but its links were inconsistent in our check. Confirm the right group through Searchlight and check who moderates it before sharing health information.
Project-USP9X has drafted a protocol of 33 computer cross-checks a genetics team could use to re-examine one family's result. It is a plan only: nothing has been run, and nothing here is a diagnosis. Choose a group to see its tests.
{{ toolSel.blurb }}
You are not alone, and you do not have to start from zero.
For parents, guardians, relatives, and adults living with USP9X-related syndrome.
For geneticists, neurologists, therapists, nurses, and scientists.
For friends, grandparents, companies, and anyone who wants to power the work.
Every issue has one takeaway to repeat to a relative or teacher, the science with its evidence level, what to ask the care team, and sources. Newsletters inform and never recommend a treatment change. Tap a phase to see topics.
{{ phSel.blurb }}
We never sell or share your information. Your child's medical details are never required to join.
Each priority starts from a gap we found in public sources. We promise a foundation for any future treatment, not a cure.
Gap: no longitudinal or milestone-by-age data found.
Deliverable: a published dataset showing what changes, and when.
Gap: no USP9X-specific surveillance or management guideline found.
Deliverable: first recommendations, written with families at the table.
Gap: no patient-derived cell or organoid study identified.
Deliverable: shared, characterized models for academic labs.
Gap: no validated biomarker or trial-ready assay found.
Deliverable: a trial-readiness toolkit.
Gap: no USP9X-specific foundation or family guide found.
Deliverable: a living guide and a moderated community.
Gap: clinicians do not know USP9X; some families wait years.
Deliverable: a one-page clinical summary and measurable outreach.